A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas
Principal Investigator
Barbara Fisher, MD
Status
Terminated
Date Opened To Accrual
January 26 2005
Date Closed to Accrual
August 11 2009
Date of Study Termination
May 20 2022
Disease Site
Brain [BN]
Lower Grade Glioma
Phase
II
Developmental Therapeutics
No
Primary Objective
To compare the 3-year survival of this regimen to the 3-year survival of the EORTC high-risk low-grade glioma population described by Pignatti et al.
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
Histologic proof of supratentorial WHO grade II astrocytoma, oligodendroglioma or oligoastrocytoma confirmed by central pathology review prior to registration. Patient must have at least three of the following risk factors: Age >/= 40; Largest preoperative diameter of tumor >/= 6 cm; Tumor crosses midline; Tumor subtype of astrocytoma (astrocytoma dominant); Preoperative Neurological Function Status > 1.
Target Accrual
135
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.